Business Context and Reporting Period
This Form 8-K, dated September 10, 2021, reports that InMed Pharmaceuticals Inc. (InMed) entered into a definitive agreement to acquire BayMedica, Inc. InMed is an emerging growth company incorporated in British Columbia, Canada, with its common shares trading on The Nasdaq Stock Market under the symbol "INM".
Key Financial Metrics and Transaction Terms
The filing details the consideration for the acquisition of BayMedica rather than reporting standard operating financial metrics such as revenue or profit for a specific period.
- Share Issuance: Approximately 1.78 million InMed common shares will be issued to BayMedica's equity and convertible debt holders.
- Hold Period: Issued shares are subject to a six-month contractual hold period.
- Escrow: 470,000 of the issued shares will be held in escrow to satisfy potential post-closing indemnification claims.
- Warrants: BayMedica holders will receive Series A warrants for up to 800,000 shares (priced at 125% of the Deal Share Price) and Series B warrants for up to 800,000 shares (priced at 200% of the Deal Share Price).
- Warrant Terms: Warrants are exercisable six months after closing and expire five years from closing.
- Adjustment Mechanism: The total number of shares issuable may be reduced if BayMedica's net liabilities exceed a negotiated threshold upon financial review.
Material Changes
The primary material change is the entry into a merger agreement. Upon closing, BayMedica will merge with and into InMed's wholly-owned subsidiary, Merger Sub. The transaction is subject to customary closing conditions and requires the filing of a resale registration statement within 120 days of closing.
Outlook, Risks, and Contingencies
Regulatory and Legal: The shares are being issued pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act. The closing is contingent upon various customary conditions.
Financial Contingencies: The final equity consideration is contingent on the outcome of a financial review of BayMedica's closing balance sheet regarding net liabilities. Additionally, a portion of the equity consideration is secured in escrow for potential future claims.
Management Commentary: The filing references a press release issued on September 13, 2021, for further details, which is furnished as Exhibit 99.1.
Investor Verification Checklist
- Verify the final number of shares to be issued after the financial review of BayMedica's net liabilities.
- Confirm the "Deal Share Price" calculation once the closing date is established to determine warrant exercise prices.
- Monitor the filing of the resale registration statement required within 120 days of closing.
- Review the full text of the Agreement and Plan of Reorganization for specific closing conditions and indemnification terms.
- Check for any updates regarding the six-month hold period and escrow release conditions.